FL

Lenalidomide plus rituximab receives CHMP’s positive opinion for the treatment of adult patients with R/R FL

On the 15th November 2019, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of lenalidomide in combination with rituximab (R²) for the treatment of adult patients with relapsed/refractory (R/R) grade 1-3a follicular lymphoma (FL).1 R2 is a chemotherapy-free treatment regimen consisting of immunomodulating lenalidomide plus the anti-CD20 antibody rituximab. The combination was approved earlier this year by the U.S. Food and Drug Administration (FDA) for the treatment of patients with marginal zone lymphoma (MZL) and FL (read more here).

The positive opinion was based on the data from the multicentre phase III studies AUGMENT (NCT01938001) and MAGNIFY (NCT01996865). AUGMENT investigated the efficacy and safety of R2 in comparison with rituximab alone in 295 patients with R/R FL. The study reported improved median progression-free survival (PFS) with the R2 combination compared to the rituximab alone (39.4 months vs 14.1 months, respectively), a hazard ratio of 0.46, and the objective response rate (ORR) of 80% in patients with FL.2 Meanwhile, the MAGNIFY study explored the efficacy of R2 followed by maintenance with lenalidomide or rituximab in 370 patients with R/R FL, MZL, or mantle cell lymphoma.3 In patients with FL, the ORR was 74% and the median PFS was 30.2 months. Read the Lymphoma Hub’s coverage of the AUGMENT study and watch Mathias Rummel discussing the MAGNIFY trial.

References
  1. Celgene. Celgene Receives CHMP Positive Opinion for REVLIMID® (lenalidomide) in Combination With Rituximab for the Treatment of Adult Patients With Previously Treated Follicular Lymphoma. November 15, 2019.https://ir.celgene.com/press-releases/press-release-details/2019/Celgene-Receives-CHMP-Positive-Opinion-for-REVLIMID-lenalidomide-in-Combination-With-Rituximab-for-the-Treatment-of-Adult-Patients-With-Previously-Treated-Follicular-Lymphoma/default.aspx?utm_source=linkedin&utm_medium=social&utm_campaign=press-release&utm_content=chmp-rr  [Accessed November 15, 2019]
  2. Leonard JP. et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2019 May 10;37(14):1188–1199. DOI: 10.1200/JCO.19.00010
  3. Sharman J. et al. Interim analysis of phase IIIb MAGNIFY study of induction R2 followed by maintenance in patients with relapsed/refractory indolent non‐Hodgkin lymphoma. Hematol Oncol. Supplement: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano, Switzerland, 18–22 June, 2019. 2019 Jun 12; 37(S2):115–116. DOI: https://doi.org/10.1002/hon.76_2629
Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!
100% of people found this article informative